Projectes destacats

Patient-derived liver biopsy-organoids for personalized medicine in NAFLD (Non-Alcoholic Fatty Liver Disease): towards real time assessment of drug response (B-ORG)

Investigador/a principal: Pau Sancho Bru.
Finançador: Ministerio de Ciencia e Innovación .

Codi: IBEC_ProyectCompl22.

Durada: 13/04/2023 - 31/12/2024
Dissecting the role of the 14q32 region in hepatoblastoma Hblast14

Investigador/a principal: Pau Sancho Bru.
Finançador: Worldwide Cancer Research .

Codi: INT_WWCR_22.

Durada: 01/04/2023 - 31/03/2026
Off the shelf hepatic stellate cells for liver disease modeling and drug screening

Investigador/a principal: Pau Sancho Bru.
Finançador: Instituto de Salud Carlos III .

Codi: FIS_DTS22.

Durada: 01/01/2023 - 31/12/2025
Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH transition to inform early prevention and treatment strategies. (Halt-RONIN)

Investigador/a principal: Pau Sancho Bru.
Finançador: European Commission .

Durada: 01/12/2022 - 30/11/2026
Mechanisms of impaired liver regeneration in alcoholic liver disease: drivers and therapeutic targets

Investigador/a principal: Pau Sancho Bru.
Finançador: Instituto de Salud Carlos III .

Codi: PI20/00765.

Durada: 01/01/2021 - 31/12/2023
Understanding hepatoblastoma to design new personalized treatments (HB-Project)

Investigador/a principal: Pau Sancho Bru.
Finançador: Asociación Española Contra el Cáncer (AECC). .

Codi: AECC-Proyectos19.

Durada: 01/12/2019 - 30/11/2022
Liver-enriched Transcription Factors as Prognostic Markers and Therapeutic Targets in Alcoholic Hepatitis (LiverTF)

Investigador/a principal: Pau Sancho Bru.
Finançador: National Institutes of Health (NIH) .

Codi: 5U01AA026972.

Durada: 22/09/2018 - 30/06/2020

La recerca d'aquest grup es pot dur a terme gràcies als finançadors.

Projectes destacats

Patient-derived liver biopsy-organoids for personalized medicine in NAFLD (Non-Alcoholic Fatty Liver Disease): towards real time assessment of drug response (B-ORG)

Dissecting the role of the 14q32 region in hepatoblastoma Hblast14

Off the shelf hepatic stellate cells for liver disease modeling and drug screening

Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH transition to inform early prevention and treatment strategies. (Halt-RONIN)

Mechanisms of impaired liver regeneration in alcoholic liver disease: drivers and therapeutic targets

Understanding hepatoblastoma to design new personalized treatments (HB-Project)

Liver-enriched Transcription Factors as Prognostic Markers and Therapeutic Targets in Alcoholic Hepatitis (LiverTF)

Finançadors principals